Revolution Medicines CFO Sells 20,000 Shares in Planned Transaction
Jack Anders, CFO of Revolution Medicines, sold 20,000 shares in a planned move worth $3.37 million.
Key Points
- Jack Anders, CFO of Revolution Medicines, sold 20,000 shares on June 24, 2026, for $168.33 each, totaling $3.37 million.
- Shares of NasdaqGS:RVMD traded near $182.08 on Saturday with a market cap of $38.71 billion and a forward P/E of -31.93.
- Vanguard Capital Management opened a new position in Revolution Medicines with 8,362,284 shares worth $813.23 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (NasdaqGS:RVMD), sold 20,000 shares of the company on June 24, 2026. This planned transaction was executed at an average price of $168.33 per share, amounting to approximately $3.37 million.
Insider Buying and Selling at Revolution Medicines, Inc.
Jack Anders, the CFO, executed a planned sale of 20,000 shares on June 24, 2026, at $168.33 per share, totaling about $3.37 million. This transaction was part of a Rule 10b5-1 trading plan. Other insiders, including Lorence Kim and Flavia Borellini, reported recent transactions, mostly involving purchases.
Other Institutional Activity in Revolution Medicines
Farallon Capital Management trimmed its holdings by 978,000 shares, leaving it with 13,604,796 shares valued at approximately $1.32 billion. BlackRock, Inc. increased its stake by 2,286,050 shares, resulting in a total of 11,212,706 shares worth about $1.09 billion, reflecting a 25.6% increase. Janus Henderson Group reduced its position by 2,537,006 shares, now holding 9,766,496 shares valued at $949.54 million. Meanwhile, Vanguard Capital Management opened a new position, acquiring 8,362,284 shares valued at $813.23 million.
Revolution Medicines, Inc. Stock Down 12.4%
Shares of Revolution Medicines traded near $182.08 on Saturday. The company has a market cap of approximately $38.71 billion. Its forward P/E ratio stands at -31.93, indicating the company is not currently profitable. The stock has experienced a 52-week range from $34.00 to $184.39, with a 50-day moving average of $151.23 and a 200-day moving average of $98.50. Revolution Medicines maintains a strong financial position with a current ratio of 6.80 and a quick ratio of 6.59.
$RVMD stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 10, 2026, Evercore ISI Group maintained a 'buy' rating for Revolution Medicines with a price target of $220. RBC Capital also maintained its 'buy' rating on June 2, with a target price of $182. HC Wainwright & Co. and Oppenheimer both reiterated their 'buy' ratings with a target of $195 on June 1. The consensus among analysts is a 'strong buy', with a mean price target of $188.57 across 21 analysts.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing innovative therapies for RAS-addicted cancers. The company's pipeline includes RAS(ON) inhibitors designed to target specific RAS variants, both as standalone treatments and in combination with other therapies. Led by CEO Dr. Mark A. Goldsmith, Revolution Medicines employs 883 people and is actively engaged in clinical trials to advance its oncology solutions.
Bottom Line
Jack Anders' planned sale of 20,000 shares highlights insider activity at Revolution Medicines, a company actively developing cancer therapies. Shares traded near $182.08 recently, with strong institutional interest as evidenced by Vanguard's new position. Investors often track such insider and institutional moves for insights, though it's important to remember that insider sales can occur for many personal reasons unrelated to company performance.
Get Revolution Medicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RVMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.